Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579636 | 1.00 | ADRB2 (0.50) | ADRB2KDM4EALDH1A1PPARGPPARA | |
| SCHEMBL5200536 | 0.88 | ADRB2 (0.50) | ADRB2KDM4EALDH1A1PPARGPPARA | |
| SCHEMBL580495 | 0.80 | RIPK1 (0.44) | ADRB2KDM4EALDH1A1KMT2AHTR1A | |
| SCHEMBL579635 | 0.77 | ABCB1 (0.45) | ADRB2STAT3 | |
| SCHEMBL10835922 | 0.76 | PPARA (0.56) | PPARGPPARA | |
| SCHEMBL13761515 | 0.75 | ALOX5 (0.46) | KDM4E | |
| SCHEMBL13761466 | 0.74 | ADRB2 (0.45) | ADRB2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL26037611 | 0.74 | GABRA1 (0.55) | — | |
| SCHEMBL8534575 | 0.74 | ADRB2 (0.54) | ADRB2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL13984169 | 0.73 | ADRB2 (0.44) | ADRB2KDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633695-B1 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-1633695-A4 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7141696-B2 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1633695-A2 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | Bridge Pharma, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105692-A2 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040248987-A1 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248987-A1 | Smooth muscle spasmolytic agents | MYLK, TNNC1, MYLK2 | ADRB2 11/4885KDM4E 1444/4885ALDH1A1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.